-2.06385569521965E-05 -2.06385569521965E-05 -4.12771139042756E-05 -0.00305450642891053 0.00778073597094087 0.00856500113512059 0.00920479640063562 0.00778073597094087
Sign Up Today X
Thanks for submitting the form.
Stockreport

Is Vertex Pharmaceuticals Stock a Buy? [Yahoo! Finance]

Vertex Pharmaceuticals Incorporated (VRTX)  More Company Research Source: Yahoo! Finance
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
to the S&P 500 index, which is down about 16% from its record high at the time of writing, Vertex shares have outperformed, up 20% year to date. Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is driving record sales. The company is also poised to benefit from two recent new drug approvals by the FDA, alongside several upcoming milestones in its extensive clinical pipeline portfolio. Will these developments be enough to sustain the rally? Let's discuss whether Vertex Pharmaceuticals stock is a buy now. The past year has been transformative for Vertex, marked by the launch of Casgevy, a groundbreaking treatment for sickle cell disease patients. This one-time, gene-edited cell therapy, developed with CRISPR Therapeutics , offers a revolutionary alternative to existing treatments that typically provide only temporary relief. Heading into 2025, an even bigger game changer for the company may be Journavx, appr [Read more]
IMPACT SNAPSHOT EVENT TIME: VRTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
VRTX alerts
from News Quantified
VRTX
NEWS
VRTX
Earnings
VRTX
Analyst Actions
VRTX
SEC Filings
Stockreport

Is Vertex Pharmaceuticals Stock a Buy? [Yahoo! Finance]

Vertex Pharmaceuticals Incorporated  (VRTX) 
More Company Research Source: Yahoo! Finance
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
to the S&P 500 index, which is down about 16% from its record high at the time of writing, Vertex shares have outperformed, up 20% year to date. Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is driving record sales. The company is also poised to benefit from two recent new drug approvals by the FDA, alongside several upcoming milestones in its extensive clinical pipeline portfolio. Will these developments be enough to sustain the rally? Let's discuss whether Vertex Pharmaceuticals stock is a buy now. The past year has been transformative for Vertex, marked by the launch of Casgevy, a groundbreaking treatment for sickle cell disease patients. This one-time, gene-edited cell therapy, developed with CRISPR Therapeutics , offers a revolutionary alternative to existing treatments that typically provide only temporary relief. Heading into 2025, an even bigger game changer for the company may be Journavx, appr [Read more]
IMPACT SNAPSHOT
EVENT TIME:
VRTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS